Cebertis

Cebertis is a Basel-based biotechnology company dedicated to developing innovative medicines for cancer and immunological diseases by modulating MHC class II. Founded in 2021 by leading experts in immunology, the company focuses on the critical role that MHC class II molecules play in orchestrating immune responses. Their therapeutic approach involves creating novel biologics designed to reactivate tumor-specific T cells or restore immune tolerance in autoimmune settings. Currently in the pre-clinical stage, Cebertis is building a pipeline centered on MHC-directed therapies that aim to overcome the limitations of existing immunotherapies. The company is situated in the Muttenz life sciences hub, benefiting from the region's strong biotech ecosystem and deep expertise in T-cell biology.